Digital Continuity: The Holy Grail

Sponsored by: Dassault Systèmes

Focused on:

  • Digital
  • Biotech
  • Drugs

Date: 14 December


Time: 3PM London/10AM New York

Innovation is the life blood of any pharmaceutical or BioTech Company. The complexities intrinsic to the drug lifecycle, combined with meeting global quality and regulatory compliance requirements presents a challenging innovation environment for these companies to meet the needs of their patients and drive competitive advantage.

Dassault Systèmes can help you proactively manage this complexity; delivering digital continuity to transform the way your pharmaceutical company operates.

Dassault Systèmes 3DEXPERIENCE platform transforms the way “innovators innovate with patients” by connecting designers, engineers, marketers, and even patients in a new ‘social enterprise’. We will share how Dassault Systèmes can enable patient centric innovation in a new digital model paradigm, turning data into insight, accelerating decision-making, and optimizing change implementation. A live Q&A session will take place at the end of the presentation.

Presented by

Jean Colombel,

VP Life Sciences Industry, Dassault Systèmes

Kevin O’Leary,

Head of Quality, Regulatory and Compliance Solutions, Dassault Systèmes

Key Learning Objectives

  • Achieve greater transparency across the entire drug lifecycle, from R&D, through Regulatory, Manufacturing, Product Supply, and Pharmacovigilance
  • Choose the correct path towards global data harmonization and standardization, adopting standards such as IDMP
  • Drive compliance, but also improve business process and data management efficiency, resulting in a significant competitive advantage
  • Leverage a ‘Single Source of Truth’ to increase collaboration and visibility across the entire ecosystem


  • Regulatory
  • R&D
  • Manufacturing
  • Quality
  • IT
  • Compliance